Imatinib Completed Phase 2 Trials for Chronic Myelogenous Leukemia (CML) / Chronic Myelomonocytic Leukemia Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00079313Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia
NCT01003054Autologous Transplantation for Chronic Myelogenous Leukemia